Входя на эту страницу, Вы подтверждаете, что являетесь  медицинским работником.

Status message

Not the entire site translated, but only to "Magazine"

THE DYNAMICS OF BIOCHEMICAL MARKERS IN FIRST-EPISODE PSYCHOSIS PATIENTS

N.N. Petrova1, V.V. Dorofeykov2, E.E. Voinkova1
1Department of Psychiatry and Addiction of St. Petersburg State University, St. Petersburg
2P.F. Lesgaft National State University of Physical Culture, Sports and Health, St. Petersburg

Summary.Currently scientists are looking for biochemical indicators, that allow to assess objectively neurodegenerative processes in patients with schizophrenia. Our study was conducted to compare the clinical characteristics of first-episode psychosis patients with the level of neural markers (S100B protein and neuron-specific enolase) in the process of antipsychotic therapy. 47 patients were examined in acute period and at the stage of drug remission formation. The determination of neuromarkers was performed using electro-luminescent analysis method. Level of S100B and NSE were reduced in comparison with healthy control. The heterogeneity of neuromarkers dynamics during the treatment was revealed. More than half of the patients reported a decreased level of S100B and increased level of NSE. Correlations between S100B and PANSS items "guiltfeelings" (r = 0.047, p < 0.001), "depression" (r = 0.042, p < 0.05) and NSE with PANSS items "depression" (r = 0.032, p < 0,05), "unusual thought content" (r = 0,041, p < 0,01), "preoccupation" (r = 0,037, p < 0,05) were revealed. The results of the research indicate the presence of neurodestructive processes in schizophrenia, probably associated with inflammatory mechanisms, that are important for the therapeutic response and remission. S100B measuring can be useful for verification of affective disorders in first-episode psychosis patients.

References: 
  • 1. Rogozhnikova O.A. Osobennosti immuniteta u ne lechennykh bol'nykh s vpervye diagnostirovannoi shizofreniei: Diss. … kand. med. nauk. 2014. – 186 s.
  • 2. Müller N. Immunology of schizophrenia // Neuroimmunomodulation. – 2014. – No. 21. – P. 109−116.
  • 3. Semenov S.F., Golodets R.G., Avrutskii G.Ya., Mosolov S.N. i dr. Kliniko-immunologicheskie aspekty primeneniya levamizola v psikhiatricheskoi praktike // Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. – 1988. – № 1. – S. 100−107.
  • 4. Khandaker G.M. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment // Lancet Psychiatry. – 2015. – No. 3. – P. 258−70.
  • 5. Kostyukova A.B., Mosolov S.N. Neirovospalitel'naya gipoteza shizofrenii i nekotorye novye terapevticheskie podkhody // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2013. – № 4. – S. 8−17.
  • 6. Iznak A.F. Regressionnye modeli svyazi klinicheskikh i neirobiologicheskikh pokazatelei pri terapii maniakal'no-bredovykh sostoyanii v ramkakh pristupoobraznoi shizofrenii // Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. – 2016. – № 3. – S. 33−38.
  • 7. Orlova V.A. Anomalii urovnei syvorotochnykh autoantitel k antigenam nervnoi tkani u bol'nykh shizofreniei: mul'tiparametricheskaya immunologicheskaya otsenka // Sotsial'naya i klinicheskaya psikhiatriya. – 2015. – № 4. – S. 45−53.
  • 8. Klyushnik T.P. Immunologicheskii monitoring endogennykh pristupoobraznykh psikhozov // Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. – 2014. – T. 114, № 2.– S. 37−41.
  • 9. Boyadzhin A.S. Markery disfunktsii apoptoza pri shizofrenii // Molekulyarnaya biologiya. – 2013. – № 2. – S. 674−680.
  • 10. Yelmo-Cruz S., Morera-Fumero A.L., Abreu-González P. S100B and schizophrenia // Psychiatry and Clinical Neurosciences. – 2013. – Vol. 67. – P. 67–75
  • 11. Thelin E.P. S100B is an important outcome predictor in traumatic brain injury // J Neurotrauma. – 2013. – Vol. 30, No. 7. – P. 519−528.
  • 12. Zhukova I.A., Alifirova V.M., Zhukova N.G. Neironspetsificheskaya enolaza kak nespetsificheskii marker neirodegenerativnogo protsessa // Byul. sibirsk. med. – 2011. – № 2. – S. 15–21.
  • 13. Mosolov S.N. Shkaly psikhometricheskoi otsenki simptomatiki shizofrenii i kontseptsii pozitivnykh i negativnykh rasstroistv. − M., 2001. – 250 s.
  • 14. Schennach R. Treatment response in first episode schizophrenia // Clinical Psychopharmacology and Neuroscience. – 2012. – Vol. 10, No. 2. – P. 78−87.
  • 15. Hong W. Higher plasma S100B concentrations in schizophrenia patients, and dependently associated with inflammatory markers // Sci Rep. − 09.06.2016. − URL: http://www.readcube.com/articles/10.1038/srep27584 (data obrashcheniya: 14.07.2017).
  • 16. Kong X.Z. Genetic variation in S100B modulates neural processing of visual scenes in Han Chinese cerebral cortex // Cerebral Cortex – 2017. – Vol. 27. – P. 1326–1336.
  • 17. Zhai J. S100B gene polymorphisms predict prefrontal spatial function in both schizophrenia patients and healthy individuals // Schizophr Res. – 2012. – Vol. 134. – P. 89–94.
  • 18. Ambrée O. S100B serum levels predict treatment response in patients with melancholic depression // Int J Neuropsychopharmacol. − 14.03.2016. − URL: https://academic.oup.com/ijnp/article/19/3/pyv103/2910132/S100B-Serum-Levels-Predict-Treatment-Response-in?searchresult=1 (data obrashcheniya: 14.07.2017).
  • 19. Gulen B. Serum S100B as a surrogate biomarker in the diagnoses of burnout and depression in emergency medicine residents // Acad Emerg Med. – 2016. – Vol. 23, No. 7. – P. 786−9.
  • 20. Polyakova M. First evidence for glial pathology in late life minor depression: S100B is increased in males with minor depression // Front Cell Neurosci. − 09.10.2015. − URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598479 (data obrashcheniya: 14.07.2017).
  • 21. Vishnevskaya O.A., Petrova N.N. Suitsidal'noe povedenie bol'nykh v remissii shizofrenii // Suitsidologiya. – 2014. – № 1. – S. 35−41.
  • 22. Dorofeikov V.V. Sovremennye laboratornye tekhnologii i risk serdechno-sosudistykh oslozhnenii // Translyatsionnaya meditsina. − SPb., 2015. − S. 290−320.